Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031060 | 1.00 | DPP4 (0.61) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL29569099 | 1.00 | DPP4 (0.61) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL751142 | 0.96 | DPP4 (0.65) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL27996817 | 0.96 | DPP4 (0.65) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL751143 | 0.96 | DPP4 (0.65) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL29415456 | 0.96 | DPP4 (0.65) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL29777789 | 0.92 | DPP4 (0.54) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL9544381 | 0.92 | DPP4 (0.54) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL9544389 | 0.92 | DPP4 (0.54) | DPP4DPP9DPP8CYP1A2GRM8 | |
| SCHEMBL29777725 | 0.91 | BACE1 (0.53) | DPP4DPP9DPP8CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709425-A1 | LINKER COMPOUNDS AND LIGAND-DRUG CONJUGATES, PREPARATION METHODS AND USES THEREOF | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| WO-2024235105-A1 | LINKER COMPOUNDS AND LIGAND-DRUG CONJUGATES, PREPARATION METHODS AND USES THEREOF | BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. (CN) | 2024-11-21 | — | — | WO | claimed |
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| EP-4289857-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-12-13 | — | — | EP | claimed |
| CN-116761820-A | Pharmaceutical conjugates of glucocorticoid receptor agonists and their use in medicine | 上海森辉医药有限公司 | 2023-09-15 | — | — | CN | claimed |
| WO-2022166779-A1 | DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE | 上海森辉医药有限公司 | 2022-08-11 | — | — | WO | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| EP-2207525-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'Oréal (FR) | 2010-07-21 | — | — | EP | claimed |
| EP-2205201-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'Oreal (FR) | 2010-07-14 | — | — | EP | claimed |
| WO-2009053594-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053587-A2 | COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| WO-2009053584-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING A POLYCONDENSATE, POLYCONDENSATE AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | claimed |
| EP-4709425-A1 | LINKER COMPOUNDS AND LIGAND-DRUG CONJUGATES, PREPARATION METHODS AND USES THEREOF | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4653419-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES, AND ANTIBODY-DRUG CONJUGATE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025119337-A1 | ANTIVIRAL CONJUGATE | 苏州拓界医药有限公司 | 2025-06-12 | — | — | WO | disclosed |
| WO-2009053594-A2 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT METHOD | L'OREAL (FR) | 2009-04-30 | — | — | WO | disclosed |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | L'OREAL (FR) | 2009-01-29 | — | — | US | disclosed |
| EP-2008647-A1 | Cosmetic or pharmaceutical composition comprising a condensation polymer, cosmetic treatment method, condensation polymer and preparation method | L'Oreal (FR) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | DPP4 4791/4885DPP9 4464/4885DPP8 4640/4885 |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | CUTA, SYMPK, TPRKB | DPP4 4670/4885DPP9 4244/4885DPP8 4397/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | DPP4 4825/4885DPP9 4602/4885DPP8 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.